Jonathan Rubin - 22 Feb 2022 Form 4/A - Amendment Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Chief Medical Officer
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
22 Feb 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
25 Feb 2022, 16:15:04 UTC
Date Of Original Report
24 Feb 2022
Next filing
17 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 22 Feb 2022 Common Stock 25,000 $32.20 Direct F1
transaction SUPN Restricted Stock Units Award $0 +3,000 $0.000000 3,000 22 Feb 2022 Common Stock 3,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in four equal annual installments beginning on February 22, 2023.
F2 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F3 The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023.